Duo Xu, MD
Ophthalmology · Philadelphia, PANPI 1992117014
Payments from drug & device makers
Across 20 payments — averaging $824.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Carl Zeiss Meditec USA, Inc.$4K
- Apellis Pharmaceuticals, Inc.$3K
- Regeneron$806
- Alimera Sciences, Inc.$473
- Dutch Ophthalmic, USA$289
- plus $342 from 4 others
What the payments were for
- Consulting fees$10,23062%
- Speaking & faculty fees$4,35026%
- Travel & lodging$8625%
- Food & beverage$1,0396%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 7 | $7,841 |
| Carl Zeiss Meditec USA, Inc. | 1 | $4,000 |
| Apellis Pharmaceuticals, Inc. | 1 | $2,730 |
| Regeneron | 2 | $806 |
| Alimera Sciences, Inc. | 2 | $473 |
| Dutch Ophthalmic, USA | 3 | $289 |
| Bausch & Lomb Americas Inc. | 1 | $120 |
| Regeneron Healthcare Solutions, Inc. | 1 | $110 |
| Carl Zeiss Meditec, Inc. | 1 | $60 |
| Genentech USA, Inc. | 1 | $53 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERACITY SURGICAL$4,000
- QUATERA 700$4,000
- IOLMaster 700$4,000
- Iluvien$473
- EVA, combined machine$191
- TISSUEBLUE$191
- STELLARIS$120
- XIPERE$120
- VISUDYNE$120
- OZURDEX$120
- EYLEA$110
How this compares
$16,482 in reported general payments places this provider in the 85th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 232 | $12,977 |
| Difluprednate | 65 | $6,944 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $1,256 |
| Ketorolac Tromethamine | 63 | $1,219 |
| Atropine Sulfate | 20 | $861 |
| Brimonidine Tartrate | 40 | $724 |
| Dorzolamide Hcl | 12 | $464 |
| Latanoprost | 36 | $310 |
| ErythromycinErythromycin Base | 24 | $274 |
| Ofloxacin | 18 | $218 |
| ValacyclovirValacyclovir Hcl | 13 | $212 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 14 | $91 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Philadelphia
- Julia HallerPhiladelphia$1.5M
- Jonathan MyersPhiladelphia$660K
- Beeran MeghparaPhiladelphia$496K
- Cesar BricenoPhiladelphia$487K
- Mark BlecherPhiladelphia$357K
- Anton KolomeyerPhiladelphia$355K
- Leslie KatzPhiladelphia$159K
- Durga BorkarPhiladelphia$150K
- Bennie JengPhiladelphia$142K
- Rachel NiknamPhiladelphia$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.